Regular Article
Increase of isoprostane 8-epi-PGF2 αafter restarting smoking

https://doi.org/10.1054/plef.2001.0277Get rights and content

Abstract

Isoprostanes are known as reliable markers of in vivo oxidation injury. Cigarette smoking has been shown to be associated with a significant increase in 8-epi-PGF2 α, a major member of this family of compounds. Quitting smoking reduces 8-epi-PGF2 αvalues to normal within a couple of weeks only. In this follow-up we checked the 8-epi-PGF2 α, values in plasma, serum and urine in 28 people who restarted smoking after a quitting attempt of various duration. 8-epi-PGF2 αshows a certain increase after restarting smoking reaching a maximum after already 1 week. Continuation of smoking does not significantly further increase 8-epi-PGF2αThese data indicate a fast response of restarting as on quitting smoking on in vivo oxidation injury. The oxidation injury reflected by 8-epi-PGF2 αmay be a key pathogenetic mechanism in smoking-induced vascular injury.

References (26)

  • D. Steinberg

    Low-density lipoprotein oxidation and its pathobiological significance

    J Biol Chem

    (1997)
  • Oguogho, A. Kritz, H. Wagner, O. Sinzinger, H. 6-oxo-PGF1 αand 8-epi-PGF2 αin the arterial wall layers of various...
  • Cited by (43)

    • Influence of smoking on levels of urinary 8-iso Prostaglandin F2α

      2019, Toxicology Reports
      Citation Excerpt :

      Table 1 presents the characteristics for the 18 publications that were included in the analyses. The reasons for exclusion of 28 articles were that one evaluated the acute effects of smoking [19], one reported levels in bronchoalveolar lavage [20], two reported levels in exhaled breath condensate [21,22], one reported levels in lymphatic vessels [23], three reported plasma levels [24–26], one reported saliva levels [27], two reported levels in sputum [28,29], four reported data from diseased populations [30–33], eight had incomplete information [4,34–40], one presented log-transformed values [41], and four others reported units that could not be used [12,42–44]. A list of the 75 publications from which abstracts were screened can be found in Supplement 1.

    • Suitability of biomarkers of biological effects (BOBEs) for assessing the likelihood of reducing the tobacco related disease risk by new and innovative tobacco products: A literature review

      2018, Regulatory Toxicology and Pharmacology
      Citation Excerpt :

      Studies which measured 8-epi-PGF2α in serum or plasma found differences between S and NS as in urine (Chehne et al., 2001, 2002; Morrow et al., 1995; Oguogho et al., 2000). Interestingly, concentrations in serum were similar to those in urine and about 15-fold higher than in plasma (Oguogho et al., 2000) Levels of this BOBE upon cessation in all three biological fluids reached NS levels after approximately 3–4 weeks (Chehne et al., 2001, 2002; Oguogho et al., 2000). In the Framingham Study with more than 2800 subjects, smoking was found to be a significant predictor (p < 0.0001) for elevated urinary 8-epi-PGF2α (Keaney et al., 2003).

    • Influence of cigarette smoking on synthesis of eicosanoids, isoprostanes and lipoxygenase metabolites in apical periodontitis

      2012, Archives of Oral Biology
      Citation Excerpt :

      Furthermore, passive cigarette smoking significantly increases in vivo oxidation injury with an increase of isoprostanes favouring the development and/or progression of associated diseases.42 The cigarette smoking associated with in vivo oxidation injury almost completely disappears within 4 weeks of smoking cessation.43,44 Salivary 8-iso-PGF2α was significantly higher in CS compared to NS.45,46

    View all citing articles on Scopus
    f2

    Dr Anthony Oguogho was on sabbatical leave from the Department of Physiology, Faculty of Basic Medical Sciences, Edo State University, Ekpoma, Nigeria, supported by the Austrian Academic Exchange Division (ÖAAD).

    f1

    Correspondence to: Prof Dr Helmut Sinzinger, Wilhelm Auerswald Atherosclerosis Research Group (ASF) Vienna, Nadlergasse 1, A-1090 Vienna, Austria. Tel.: +43 1 4082633; Fax: +43 1 4081366; E-mail: [email protected]

    View full text